Publications

5674 Results

SWOG S1203: A randomized phase III study of standard cytarabine plus daunorubicin (7+3) therapy versus idarubicin with high dose cytarabine (IA) with or without vorinostat (IA+V) in younger patients with previously untreated acute myeloid leukemia (AML)

Authors
G Garcia-Manero;M Othus;J Pagel;J Radich;M Fang;DA Rizzieri;G Marcucci;S Strickland;MR Litzow;ML Savoie;B Medeiros;M Sekeres;T Lin;G Uy;BL Powell;J Kolitz;R Larson;RM Stone;D Claxton;J Essell;S Luger;S Mohan;A Moseley;FR Appelbaum;H Erba
Journal / Conference
Blood 128:901; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S1203

Feasibility of allogeneic hematopoietic cell transplantation among high-risk AML patients in first complete remission: results of the transplant objective from the SWOG (S1203) randomized phase III study of induction therapy using standard 7+3 therapy or idarubicin with high-dose cytarabine (IA) versus IA plus vorinostat

Authors
J Pagel;G Garcia-Manero;M Fang;J Radich;DA Rizzieri;G Marcucci;S Strickland;MR Litzow;ML Savoie;S Spellman;D Confer;J Chell;M Brown;B Medeiros;M Sekeres;TL Lin;G Uy;BL Powell;J Kolitz;RA Larson;RM Stone;D Claxton;J Essell;S Luger;S Mohan;A Moseley;H Erba;F Appelbaum
Journal / Conference
Blood 128:1166; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), oral
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S1203

A Phase 1 trial of inotuzumab in combination with CVP (cyclophosphamide, vincristine, prednisone) for relapsed/ refractory CD22+ acute leukemia (SWOG 1312) [ http://www.bloodjournal.org/content/128/22/1634]

Authors
A Advani;A Moseley;M Liedtke;M O'Donnell;M Othus;M Mims;K O'Dwyer;H Erba
Journal / Conference
Blood 128:1634; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S1312

Improved prognostic significance genomic and transcriptional prognostic biomarkers by examining enriched populations of AML blasts: a SWOG report

Authors
EL Pogosova-Agadjanyan;A Moseley;BL Wood;F Appelbaum;TR Chauncey;H Erba;J Godwin;M Fang;Kopecky;AF List;M Othus;J Radich;I-M Chen;CL Willman;S Meshinchi;D Stirewalt
Journal / Conference
Blood 128:2890; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S0106, S0112, SWOG-9031, SWOG-9333

Complete remissions (CRs) with azacitidine regimens compared to CRs with 7+3 induction chemotherapy and the effect on overall survival

Authors
M Othus;M Sekeres;S Nand;G Garcia-Manero;F Appelbaum;H Erba;E Estey
Journal / Conference
Blood 128:1613; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S0106, S0703, S1117, S1203

Comparable outcomes of patients eligible versus ineligible for SWOG leukemia studies

Authors
A Statler;M Othus;H Erba;T Chauncey;J Radich;S Coutre;A Advani;S Nand;F Ravandi;S Mukherjee;M Sekeres
Journal / Conference
Blood 128:4002; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S0106, S0301, S0325, S0333, S0432, S0521, S0530, S0605, S0703, S0805, S0910, S0919, S1117

Genomic subtypes of nucleophosmin (NPM1) mutations are associated with clinical outcome in AML – A COG and SWOG intergroup collaboration

Authors
D Selim;T Alonzo;M Othus;R Gerbing;F Ostronoff;K Tarlock;E Kutny;R Aplenc;A Kolb;J Radich;F Appelbaum;A Gamis;D Stirewalt;S Meshinchi
Journal / Conference
Blood 128:285; American Society of Hematology Annual Meeting (December 3-6, 2016,San Diego, CA), oral
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
S0106

Novel associations between mutations, biological and clinical parameters in untreated CLL: Data from the ECOG-E1912, a Randomized Phase III Study of the ECOG-ACRIN Cancer Research Group

Authors
E Braggio;S Garcia;V Wang;L Bruins;C Lesnick;R Fonseca;N Kay;S O'Brien;T Shanafelt
Journal / Conference
Blood 128:4373; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster
Year
2016
Research Committee(s)
Leukemia
Study Number(s)
CTSU/E1912

Neutrophil-to-lymphocyte ratio as a bladder cancer biomarker: Assessing prognostic and predictive value in SWOG 8710

Authors
E Ojerholm;A Smith;W-T Hwang;B Baumann;KN Tucker;SP Lerner;R Mamtani;B Boursi;JP Christodouleas
Journal / Conference
Cancer 2017 Mar 1;123(5):794-801; Oct 27. doi: 10.1002/cncr.30422. [Epub ahead of print]
Year
2016
Research Committee(s)
Genitourinary
PMID
PMID27787873
PMC
PMC5319875
Study Number(s)
SWOG-8710 (INT-0080) (EST-1887) (CALGB-8891)

HLA Haplotypes Are Associated with Multiple Myeloma Risk in the African American Multiple Myeloma Study (AAMMS)

Authors
L Gragert;A Hwang;L Bernal-Mizrachi;S Ailawadhi;S Singhal;D Vandenberg;X Sheng;A Stram;DV Conti;K Rand;C Song;JJ Graff;N Janakiraman;J Mehta;D Stram;C Bock;L Kolonel;G Colditz;A Mohrbacher;ES Peters;HR Terebelo;AK Nooka;R Vij;P Hari;M Beksac;BC-H Chiu;MH Tomasson;JA Zonder;CA Huff;RZ Orlowski;S Lonial;CA Haiman;W Cozen
Journal / Conference
Blood 128:3250; American Society of Hematology Annual Meeting (December 3-6, 2016, San Diego, CA), poster, abst. #3250
Year
2016
Research Committee(s)
Prevention, Screening, and Surveillance, Prevention, Screening, and and Surveillance
Study Number(s)
S0000